Get the Stockscreener App
8.16
0.00%
0.00
Pre-market:
8.50
0.34
+4.17%
Daxor Corporation stock is traded at $8.16, with a volume of 1,810.
It is up +0.00% in the last 24 hours and up +14.44% over the past month.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
See More
Previous Close:
$8.16
Open:
$8.4999
24h Volume:
1,810
Relative Volume:
0.21
Market Cap:
$39.49M
Revenue:
$2.61M
Net Income/Loss:
$1.69M
P/E Ratio:
27.17
EPS:
0.3003
Net Cash Flow:
-
1W Performance:
+5.02%
1M Performance:
+14.44%
6M Performance:
-9.70%
1Y Performance:
-4.00%
1-Day Range:
$7.7901
$8.4999
1-Week Range:
$7.55
$8.4999
52-Week Range:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Name
Daxor Corporation
Sector
Industry
Phone
212-330-8500
Address
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
8.16 | 39.49M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-19 | Initiated | Ascendiant Capital Markets | Buy |
Daxor Corporation Stock (DXR) Latest News
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor Corporation Reports Strong 2024 Financial Growth - TipRanks
Daxor CFO Michel Robert J purchases $8,000 in company stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases $25,804 in company stock - Investing.com
Daxor CFO Michel Robert J purchases $8,000 in company stock - Investing.com
Daxor Corporation Reports Robust Growth in Earnings Call - TipRanks
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth - Investing.com India
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth By Investing.com - Investing.com UK
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Daxor Corporation Reports Increase in NAV to $7.25 Per - GlobeNewswire
How Daxor Achieved Triple-Digit Revenue Growth: 60% Kit Sales Spike and DoD Contract Success - StockTitan
Daxor Corporation to Host Investor Conference Call to - GlobeNewswire
When Will Daxor Share Its 2024 Results? Key Date for Blood Volume Tech Investors - StockTitan
(DXR) Investment Report - Stock Traders Daily
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - Marketscreener.com
How Daxor Achieved 116% Revenue Growth and Cash-Flow Break-Even: CEO Reveals Strategy - StockTitan
Daxor reports significant growth and strategic advances - Investing.com
Daxor reports significant growth and strategic advances By Investing.com - Investing.com South Africa
Daxor Corporation Reports Significant Growth and Strategic Developments in Blood Volume Measurement Technology - Nasdaq
How Daxor Doubled Revenue and Reached Cash-Flow Break-Even: CEO's Strategic Vision Revealed - StockTitan
How Daxor's 116.5% Revenue Explosion Could Transform Its Medical Diagnostics Business - StockTitan
Daxor Expands Blood Volume Analysis Services At Major Midwest Healthcare Center - Marketscreener.com
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center - The Manila Times
How Daxor's No-Capital-Cost Diagnostic Service Is Quietly Expanding Across Major Healthcare Systems - StockTitan
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - GlobeNewswire
Can Daxor's Hospital Expansion Strategy Transform Critical Care Outcomes? - StockTitan
Head to Head Comparison: Daxor (NASDAQ:DXR) versus iRhythm Technologies (NASDAQ:IRTC) - Defense World
Long Term Trading Analysis for (DXR) - Stock Traders Daily
Daxor Corporation Announces New Data on Blood Volume - GlobeNewswire
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 - The Manila Times
Duke and Yale Studies Validate Daxor's Blood Volume Analysis Superior Accuracy | DXR Stock News - StockTitan
Daxor to Exhibit at World's Largest Critical Care Conference - GlobeNewswire
Revolutionary ICU Blood Analysis Slashes Death Rates: Daxor's Game-Changing Data Revealed - StockTitan
DXRDaxor Corporation Latest Stock News & Market Updates - StockTitan
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure - GlobeNewswire
Hidden Heart Failure Risk Affects Millions: Daxor's Revolutionary Blood Test Unlocks Life-Saving Treatment Path - StockTitan
Daxor Corporation Announces Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care - Marketscreener.com
Daxor Hikeson Blood Study - Baystreet.ca
New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care - GlobeNewswire
Major Clinical Study: Revolutionary Heart Failure Diagnostic Achieves Near-Perfect Accuracy - StockTitan
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
(DXR) Investment Analysis and Advice - Stock Traders Daily
Where are the Opportunities in (DXR) - Stock Traders Daily
Reviewing Becton, Dickinson and Company (NYSE:BDX) and Daxor (NASDAQ:DXR) - Defense World
(DXR) Technical Pivots with Risk Controls - Stock Traders Daily
Daxor Corporation Stock (DXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):